Brief: BioInvent Announces Additional Efficacy Data From Phase 1/2 Trial With BI-1206 In Solid Tumors
07/06/2023 12:14
June 7 (Reuters) - BioInvent International AB BINV.ST :
* BIOINVENT ANNOUNCES ADDITIONAL EFFICACY DATA FROM
INTRAVENOUS
PART OF PHASE 1/2 TRIAL WITH BI-1206 IN SOLID TUMORS
* ONE ADDITIONAL PATIENT HAS DEVELOPED A PARTIAL RESPONSE
(PR) AND
ONE PATIENT HAS REMAINED ON STABLE DISEASE FOR OVER 80 WEEKS
* THESE LONG-LASTING RESPONSES IN HARD-TO-TREAT METASTATIC
DISEASES, IN PATIENTS WHO HAD PREVIOUSLY PROGRESSED AFTER
TREATMENT WITH ANTI-PD1/PDL1 AGENTS, STRONGLY SUGGEST THAT
BI-1206 IS ENHANCING AND RECOVERING ACTIVITY OF PEMBROLIZUMAB
(AN ANTI-PD1 AGENT)
Source text for Eikon: ID:nMFN6k3bbL
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))